CG Oncology Is Building A Best-In-Class Profile In NMIBC
Cretostimogene Phase III Data Look Competitive
The biotech’s Phase III data with an oncolytic immunotherapy for non-muscle invasive bladder cancer shows high complete response rates, duration of response and good safety/tolerability.
